Inozyme Pharma Inc expected to post a loss of 61 cents a share - Earnings Preview

Inozyme Pharma

08/11/2021 14:17

* Inozyme Pharma Inc  INZY.OQ   INZY.O  is expected to show no
change in quarterly revenue when it reports  results on November
10 (estimated). 
​* Refinitiv's mean analyst estimate for Inozyme Pharma Inc is
for a loss of 61 cents per share. For the same quarter last
year, the company reported a loss of $1.55 per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Inozyme Pharma
Inc is $37​, about 73.1% above​ its last closing price
of $9.97. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.57       -0.57      -0.53     Beat    7
 Mar. 31 2021  -0.54       -0.54      -0.47     Beat    13.2
 Dec. 31 2020              -0.55      -1.01     Missed  -85​
 Sep. 30 2020  -0.51       -0.51      -1.55     Missed  -203.9
 ​​Jun.        -1.41       -1.41      -7.57     Missed  -435.9
 30 2020                                                
                                                        ​
 This summary was machine generated November 8 at 14:17 GMT.  All
figures in US dollars unless otherwise stated